Rodríguez-Lescure, Álvaro http://orcid.org/0000-0002-6823-5290
Gallego, Javier
Garcia-Alfonso, Pilar
Massuti, Bartomeu
Márquez, Raúl
Calvo, Lourdes
Sánchez-Rovira, Pedro
Antón, Antonio
Chacón, José Ignacio
Ciruelos, Eva
Ponce, Jose Juan
Santaballa, Ana
Valladares-Ayerbes, Manuel
Dueñas, María Rosario
Alonso, Vicente
Aparicio, Jorge
Encinas, Sara
Robles, Luis
Escudero, María José
Caballero, Rosalía
Bezares, Susana
de la Haba-Rodriguez, Juan
Funding for this research was provided by:
Sociedad Española de Oncología Médica (SEOM FECMA 2018)
Instituto de Salud Carlos III (Proyecto multicéntrico, expediente FIS PI15/00516)
Roche España
Article History
Received: 27 October 2023
Accepted: 16 February 2024
First Online: 5 April 2024
Declarations
:
: Rodríguez-Lescure A has received consultant or advisory role from Roche, Lilly, Pfizer, Novartis, Daiichi-Sankyo and Astra-Zeneca; Speaker’s bureau fees from Daiichi-Sankyo, Merck and Astra-Zeneca. Gallego J has received consultant or advisory role from Amgen, Astellas, Bayer, BMS, Eisai, Ipsen, Lilly, Merck, MSD, Pierre-Fabre, Roche, Servier and Veracyte; Speaker’s bureau fees from Amgen, Bayer, BMS, Ipsen, Lilly, Merck, MSD, Novartis and Servier; Educational grants from Amgen, Ipsen, Merck, Novartis, Pierre-Fabre and Roche. Garcia-Alfonso P has received consultant or advisory role fees and Speaker’s bureau fees from Amgen, Merck Serono, MSD, Lilly, Roche, Sanofi, Servier and Pierre Fabre. Massuti B has received consultant or advisory role from Roche, Boehringer Ingelheim, Astra Zeneca, Merck Serono and Janssen; Speaker’s bureau fees from Roche, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Sanofi/Regeneron, Janssen Oncology and Pfizer; Travel accommodations expenses from Roche, MSD and Astra Zeneca. Ponce J has received consultant or advisory role from Astra Zeneca, Daiichi Sankyo, Novartis, Pierre Fabre, Roche and Seattle Genetics; Speaker’s bureau fees from Astra Zeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer and Seattle Genetics. Santaballa A has received consulting or advisory role fees from GSK, Clovis, MSD, Astra Zeneca, Pfizer, Novartis and Lilly; Speaker’s bureau fees from GSK, Clovis, MSD, Astra Zeneca, Pfizer, Novartis, Lilly and Pierre Fabre; Travel accommodations expenses from Pfizer and MSD. Valladares M has received consulting or advisory role fees from Amgen, Servier and Bayer; Speaker’s bureau fees from Merk, Amgen, Servier, Bayer, Roche and Celgene; Research funding from Amgen and Roche; Travel accommodations expenses from Roche, Merk, Amgen and Servier. Alonso V has received consulting or advisory role fees from Sanofi, Amgen, Merk, Servier and Novartis; Travel accommodations expenses from Roche and Merk. Aparicio J has received consultant or advisory role fees from Amgen, Bayer, Merck, Merck Sharp & Dohme, Pierre Fabre and Servier. The rest of authors have declared no conflicts of interest.